Skip to main content

Table 2 Characteristics of all included HIV-1 patients and patients included in the years 2002 to 2005 and 2006 to 2007

From: Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

Characteristics

Categories

Total

2002-2005

2006-2007

Patients

 

4317

2687

1630

Continent of origin, no (%)

Western Europe

2404 (56)

1608 (60)

796 (49)

Eastern Europe & Central Asia

919 (21)

424 (16)

495 (30)

Sub-Saharan Africa

472 (11)

323 (12)

149 (9)

Other

354 (8)

190 (7)

164 (10)

Unknown

168 (4)

142 (5)

26 (2)

Gender, no. (%)

Male

3411 (79)

2080 (77)

1331 (82)

Risk group, no. (%)

MSM

2084 (48)

1230 (46)

854 (52)

Hetero

1501 (35)

1004 (37)

497 (30)

Injecting drug use

355 (8)

208 (8)

147 (9)

Unknown

377 (9)

245 (9)

132 (8)

Subtype, no. (%)

B

2855 (66)

1777 (66)

1078 (66)

non-B

1381 (32)

849 (32)

532 (33)

Unknown

81 (2)

61 (2)

20 (1)

Duration of infection, no (%)

<1 year

1236 (29)

724 (27)

512 (31)

1-2 years

144 (3)

77 (3)

67 (4)

Unknown

2937 (68)

1886 (70)

1051 (64)

Plasma HIV-RNA, median (IQR), log copies/ml

4.9 (4.3-5.3)

4.9 (4.3-5.3)

4.8 (4.2-5.4)

CD4 cell count, median (IQR), cells/mm3

352 (180–540)

343 (163–533)

370 (210–548)

Age, median years (IQR)

35 (29–42)

35 (29–42)

35 (29–42)